• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amgen (NQ: AMGN )

    316.91 -2.31 (-0.72%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amgen

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    46 47 Next >
    Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF
    Covered calls can generate income from an investment portfolio but can be complex. This Amplify ETF is a simple solution. 
    Via The Motley Fool
    Topics ETFs
    So Much For Expecting The Fed To Stick The Landing
    Now is not the time to be fully invested. 
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    Amgen's Options: A Look at What the Big Money is Thinking
    Via Benzinga
    3 Biotech Stocks That Could Have Investors Grinning Soon
    Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
    Via InvestorPlace
    Prediction: This Could Be Amgen's Next Massive Growth Opportunity
    The innovative biotech is looking for its next blockbuster. 
    Via The Motley Fool
    The Top 3 Biotech Stocks to Buy Now Summer 2024
    These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
    Via InvestorPlace
    $100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today
    Via Benzinga
    Unpacking the Latest Options Trading Trends in Amgen
    Via Benzinga
    Market Whales and Their Recent Bets on AMGN Options
    Via Benzinga
    Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
    Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    3 Dividend-Paying ETFs to Secure Your Passive Income Stream
    Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs? 
    Via InvestorPlace
    Topics ETFs
    3 Fabulous Growth Stocks to Buy and Hold Forever
    The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
    Via InvestorPlace
    Unpacking the Latest Options Trading Trends in Amgen
    Via Benzinga
    A Closer Look at Amgen's Options Market Dynamics
    Via Benzinga
    7 Biotech Stocks to Keep on Your Clinical Radar
    Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
    Via InvestorPlace
    3 Stocks That Are Melting Up. Is There Room to Run?
    Buying stocks while they're melting up isn't without its fair share of risk. That said, these high-flyers look pretty enticing. 
    Via InvestorPlace
    10 Best Dividend Growth Stocks to Buy and Hold Forever
    Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance. 
    Via The Motley Fool
    Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
    The Nasdaq tumbled amid chip woes. 
    Via Investor's Business Daily
    Q2 Earnings Season Scorecard, Economic Outlook And Analyst Reports For Nvidia, Meta & Others
    Today's Research Daily features a real-time update on the Q2 earnings season, the July Economic Outlook monthly, and new research reports on 16 major stocks, including NVIDIA, Meta, and Amgen as well... 
    Via Talk Markets
    EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
    Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
    Via Benzinga
    Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
    Roche released early-stage data on its oral weight-loss drug. 
    Via Investor's Business Daily
    7 Dividend Stocks That Just Raised Their Payouts: July 2024
    Dividend stocks have a long history of outperforming non-dividend-paying stocks, but those that increase their payout do even better. 
    Via InvestorPlace
    Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
    Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
    Via Investor's Business Daily
    3 Quantum AI Stocks That Could Redefine Computing
    Three quantum AI stocks could shape the future of computing, which means current market prices are very cheap. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Biotech Stocks to Buy Now: Q3 Edition
    Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
    Via InvestorPlace
    CPI Data Sparks Rally in Biotech Stocks
    Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
    Via MarketBeat
    Topics ETFs Economy
    Exposures Interest Rates
    What Is the Dividend Payout for Amgen Stock?
    Amgen offers a packed pipeline and healthy dividend distributions. 
    Via The Motley Fool
    Positive News is Driving This Cancer Drug Maker’s Stock Higher
    IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
    Via MarketBeat
    Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
    Revenue is climbing at these two drug companies -- and the trend should continue. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    46 47 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.